A genetic medicines company in Massachusetts that focuses on patients suffering from rare genetic diseases.
The company has developed a novel set of adeno-associated virus vectors derived from human hematopoietic stem cells (AAVHSCs) that are designed to precisely and efficiently deliver genetic medicines in vivo either through gene therapy or by harnessing the body’s natural DNA repairDNA repair process of homologous recombination through nuclease-free gene editing.